SCHEMBL5835265

SCHEMBL5835265

COc1ccc(S(=O)(=O)Nc2ccc(Cl)c(OC3CCN(C)C3)c2)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 10/20 0.73
LMNA P02545 4/20 0.58
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 5/20 0.54
PKM P14618 2/20 0.54
TSHR P16473 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
GAA P10253 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
GHSR Q92847 1/20 0.50
HTR6 P50406 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835262 1.00 UTS2R (0.73) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835321 1.00 UTS2R (0.73) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835460 0.91 UTS2R (0.67) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835457 0.91 UTS2R (0.67) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835421 0.89 LMNA (0.59) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835427 0.89 LMNA (0.59) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL7128200 0.89 UTS2R (0.67) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL7128201 0.89 UTS2R (0.67) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835685 0.89 UTS2R (0.58) UTS2RLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL5835662 0.89 UTS2R (0.58) UTS2RLMNAHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885LMNA 3610/4885HTT 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.